Managers / Q1 2022 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$242M
Q1 2022
Positions
49
Filings on Record
30
2019–present window
Filed
May 9, 2022
original filing
Summary
Sivik Global Healthcare LLC reported $242M in U.S.-listed holdings across 49 positions for Q1 2022.
Its largest position, XBI, represents 5.6% of the portfolio.
Compared with Q4 2021, the fund opened 15 new positions and exited 11.
Portfolio Metrics
Turnover
+24.0%
vs prior filed quarter
Top-10 Concentration
+34.3%
share of reported value
Largest Position
+5.6%
Spdr S P Biotech Etf
New / Exited
15 / 11
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 88.5% · $214M
- ETP · 5.6% · $13M
- ADR · 3.7% · $9M
- Other · 2.2% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CNCCentene Corp | NEW | +70.0K | 70.0K | +$6M | $6M |
| NVONovo Nordisk A/S | NEW | +45.0K | 45.0K | +$5M | $5M |
| CICigna Corp | NEW | +20.0K | 20.0K | +$5M | $5M |
| MDTMedtronic PLC | NEW | +35.0K | 35.0K | +$4M | $4M |
| AMEDAmedisys Inc | NEW | +20.0K | 20.0K | +$3M | $3M |
| LHC Group Inc | NEW | +20.0K | 20.0K | +$3M | $3M |
| ACHCAcadia Healthcare Co Inc | NEW | +50.0K | 50.0K | +$3M | $3M |
| SGRYSurgery Partners Inc | NEW | +57.0K | 57.0K | +$3M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2022
49 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | XBISPDR S&P Biotech ETFhistory → | Cash Securities | 5.57% | $13M | 150.0K |
| 2 | BSXBoston Scientific Corphistory → | Cash Securities | 3.66% | $9M | 200.0K |
| 3 | UNHUnitedHealth Group Inchistory → | Cash Securities | 3.58% | $9M | 17.0K |
| 4 | DHRDanaher Corphistory → | Cash Securities | 3.33% | $8M | 27.5K |
| 5 | HUMHumana Inchistory → | Cash Securities | 3.23% | $8M | 18.0K |
| 6 | THCTenet Healthcare Corphistory → | Cash Securities | 3.19% | $8M | 90.0K |
| 7 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 3.05% | $7M | 12.5K |
| 8 | ELVAnthem Inchistory → | Cash Securities | 3.04% | $7M | 15.0K |
| 9 | MCKMcKesson Corphistory → | Cash Securities | 2.84% | $7M | 22.5K |
| 10 | UHSUniversal Health Services Inchistory → | Cash Securities | 2.84% | $7M | 47.5K |
| 11 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 2.80% | $7M | 22.5K |
| 12 | JNJJohnson & Johnsonhistory → | Cash Securities | 2.56% | $6M | 35.0K |
| 13 | CORAmerisourceBergen Corphistory → | Cash Securities | 2.55% | $6M | 40.0K |
| 14 | AVTRAvantor Inchistory → | Cash Securities | 2.51% | $6M | 180.0K |
| 15 | CVSCVS Health Corphistory → | Cash Securities | 2.51% | $6M | 60.0K |
| 16 | CNCCentene Corphistory → | Cash Securities | 2.43% | $6M | 70.0K |
| 17 | EHCEncompass Health Corphistory → | Cash Securities | 2.42% | $6M | 82.4K |
| 18 | Charles River Laboratories In | Cash Securities | 2.34% | $6M | 20.0K |
| 19 | HCAHCA Healthcare Inchistory → | Cash Securities | 2.33% | $6M | 22.5K |
| 20 | SYKStryker Corphistory → | Cash Securities | 2.21% | $5M | 20.0K |
| 21 | ABTAbbott Laboratorieshistory → | Cash Securities | 2.20% | $5M | 45.0K |
| 22 | Laboratory Corp of America Ho | Cash Securities | 2.18% | $5M | 20.0K |
| 23 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 2.11% | $5M | 40.0K |
| 24 | NVONovo Nordisk A/Shistory → | Cash Securities | 2.06% | $5M | 45.0K |
| 25 | GMEDGlobus Medical Inchistory → | Cash Securities | 1.98% | $5M | 65.0K |
| 26 | CICigna Corphistory → | Cash Securities | 1.98% | $5M | 20.0K |
| 27 | BAXBaxter International Inchistory → | Cash Securities | 1.92% | $5M | 60.0K |
| 28 | IQVIQVIA Holdings Inchistory → | Cash Securities | 1.91% | $5M | 20.0K |
| 29 | MDTMedtronic PLChistory → | Cash Securities | 1.60% | $4M | 35.0K |
| 30 | OPCHOption Care Health Inchistory → | Cash Securities | 1.53% | $4M | 130.0K |
| 31 | CYHCommunity Health Systems Inchistory → | Cash Securities | 1.47% | $4M | 300.0K |
| 32 | AMEDAmedisys Inchistory → | Cash Securities | 1.42% | $3M | 20.0K |
| 33 | LHC Group Inc | Cash Securities | 1.39% | $3M | 20.0K |
| 34 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 1.35% | $3M | 50.0K |
| 35 | ABBVAbbVie Inchistory → | Cash Securities | 1.34% | $3M | 20.0K |
| 36 | SGRYSurgery Partners Inchistory → | Cash Securities | 1.30% | $3M | 57.0K |
| 37 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.29% | $3M | 130.0K |
| 38 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 1.27% | $3M | 40.0K |
| 39 | NVSTEnvista Holdings Corphistory → | Cash Securities | 1.21% | $3M | 60.0K |
| 40 | LLYEli Lilly & Cohistory → | Cash Securities | 1.18% | $3M | 10.0K |
| 41 | INCYIncyte Corphistory → | Cash Securities | 1.15% | $3M | 35.0K |
| 42 | GHGuardant Health Inchistory → | Cash Securities | 1.09% | $3M | 40.0K |
| 43 | Seagen Inc | Cash Securities | 1.04% | $3M | 17.5K |
| 44 | GRFSGrifols SA | Cash Securities | 0.96% | $2M | 200.0K |
| 45 | CAHCardinal Health Inc | Cash Securities | 0.94% | $2M | 40.0K |
| 46 | NBIXNeurocrine Biosciences Inc | Cash Securities | 0.87% | $2M | 22.5K |
| 47 | NTRANatera Inc | Cash Securities | 0.84% | $2M | 50.0K |
| 48 | MRNAModerna Inc | Cash Securities | 0.71% | $2M | 10.0K |
| 49 | BNTXBioNTech SE | Cash Securities | 0.70% | $2M | 10.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.